```html

Zollinger’s Enteritis – A Comprehensive Medical Guide

Overview

Zollinger’s enteritis is not a distinct, widely recognized medical entity in current gastroenterology literature. The term most often appears as a mis‑interpretation of Zollinger‑Ellison syndrome (ZES), a rare condition in which one or more gastrin‑producing tumors (gastrinomas) cause excessive gastric acid secretion, leading to severe peptic ulcer disease and, occasionally, inflammatory changes in the small intestine. Because “enteritis” denotes inflammation of the intestinal lining, some older case reports loosely used “Zollinger’s enteritis” to describe intestinal inflammation secondary to uncontrolled acid exposure.

For the purpose of this guide, we will focus on the pathophysiology, presentation, and management of Zollinger‑Ellison syndrome and its intestinal manifestations, providing practical information that patients and caregivers can use.

Who it affects: ZES can affect anyone but is most commonly diagnosed in adults aged 30‑60 years. Men and women are affected equally.

Prevalence: The estimated incidence is about 0.5–2 cases per million people per year worldwide, making it a rare disorder. Approximately 20‑30 % of patients with ZES have multiple endocrine neoplasia type 1 (MEN‑1), a hereditary condition that predisposes to several endocrine tumors.

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), European Neuroendocrine Tumor Society.

Symptoms

Symptoms result from two main mechanisms: (1) hyperacidic stomach secretions and (2) the local or metastatic effects of gastrin‑producing tumors.

Gastro‑intestinal symptoms

• Refractory peptic ulcers – ulcers that fail to heal with standard therapy; may occur in the duodenum, jejunum, or even distal small intestine.
• Abdominal pain – often described as gnawing or burning; can be intermittent or continuous.
• Diarrhea – caused by acid inactivation of pancreatic enzymes and bile salts, leading to malabsorption.
• Steatorrhea (fatty stools) – a sign of fat malabsorption due to pancreatic insufficiency.
• Nausea & vomiting – especially after meals.
• Weight loss – secondary to malabsorption and chronic diarrhea.

Systemic symptoms

• Heartburn / gastro‑esophageal reflux disease (GERD).
• Fatigue – from anemia (chronic blood loss) or nutrient deficiencies.
• Hypokalemia – low potassium due to chronic diarrhea.
• Metastatic signs – if the gastrinoma spreads (commonly to the liver or lymph nodes), patients may develop abdominal masses, jaundice, or bone pain.

Causes and Risk Factors

Primary cause

Zollinger‑Ellison syndrome is caused by gastrinomas, neuroendocrine tumors that secrete excess gastrin. Gastrin stimulates parietal cells to produce hydrochloric acid, leading to the hyperacidic environment.

Risk factors

• Multiple endocrine neoplasia type 1 (MEN‑1) – hereditary mutation in the MEN1 gene; accounts for ~25 % of ZES cases.
• Familial gastrinoma syndrome – rare autosomal‑dominant inheritance without other MEN‑1 features.
• Age – risk increases after the third decade of life.
• Smoking – may promote neuroendocrine tumor development.
• Chronic H. pylori infection – not a direct cause but can exacerbate ulcer disease in patients with ZES.

There is no clear lifestyle or environmental trigger for sporadic gastrinomas.

Diagnosis

Because the presentation mimics common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory or multiple.

Step‑wise diagnostic approach

1. Laboratory testing
   • Fasting serum gastrin level – markedly elevated (>1000 pg/mL) strongly suggests ZES. Levels can be modestly high in renal failure or proton‑pump inhibitor (PPI) use, so these conditions must be considered.
   • Secretin stimulation test – administration of secretin paradoxically raises gastrin in ZES; a rise >120 pg/mL is diagnostic.
   • Chromogranin A – a general neuroendocrine tumor marker; may be elevated.
2. Imaging studies
   • Contrast‑enhanced CT or MRI – detects primary tumor and metastases.
   • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumors.
   • Endoscopic ultrasound (EUS) – excellent for locating small pancreatic or duodenal gastrinomas.
3. Endoscopy
   • Upper GI endoscopy to document ulcer disease; biopsies rule out H. pylori and malignancy.
4. Genetic testing (when MEN‑1 is suspected)
   • Sequencing of the MEN1 gene; counseling recommended.

Diagnosis is confirmed when elevated gastrin levels are documented and a gastrinoma is identified on imaging or during surgery.

Treatment Options

Medical therapy – control of acid hypersecretion

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; they reduce acid output, promote ulcer healing, and improve symptoms. Doses may be 3–5 times the standard ulcer dose and are titrated to the lowest effective amount.
• Histamine‑2 receptor antagonists (H2RAs) – less effective than PPIs but may be added for breakthrough symptoms.
• Antacids – provide symptomatic relief but do not treat the underlying hypersecretion.

Surgical management – tumor removal

• Localized gastrinoma – en‑bloc resection of the tumor (pancreaticoduodenectomy, distal pancreatectomy, or duodenal excision) offers potential cure.
• Multiple or metastatic disease – cytoreductive surgery may reduce tumor burden; liver metastases can be resected, ablated, or embolized.

Targeted and systemic therapies

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may shrink tumor size.
• Peptide receptor radionuclide therapy (PRRT) – uses radiolabeled somatostatin analogues for metastatic neuroendocrine tumors.
• Chemotherapy – reserved for high‑grade or rapidly progressive disease; regimens often include streptozocin, 5‑FU, or temozolomide.

Lifestyle and supportive measures

• Eat small, frequent meals to reduce acid spikes.
• Avoid foods that trigger reflux (caffeine, alcohol, spicy foods, chocolate).
• Stay hydrated; oral rehydration solutions help replace lost electrolytes from diarrhea.
• Supplement fat‑soluble vitamins (A, D, E, K) and calcium if steatorrhea persists.

Living with Zollinger’s Enteritis (Zollinger‑Ellison Syndrome)

Daily management tips

1. Medication adherence – take PPIs exactly as prescribed; never skip doses.
2. Monitoring – keep a symptom diary (pain, stool pattern, weight). Report new or worsening symptoms to your gastroenterologist.
3. Nutrition
   • Consider a low‑fat diet if steatorrhea is prominent.
   • Include medium‑chain triglyceride (MCT) oil, which is easier to absorb.
   • Work with a dietitian experienced in neuroendocrine tumors.
4. Regular follow‑up – imaging and gastrin levels are usually checked every 6–12 months.
5. Vaccinations – patients on somatostatin analogues or PRRT may have altered immune response; keep vaccines up‑to‑date (influenza, pneumococcal, COVID‑19).
6. Psychosocial support – chronic disease can cause anxiety; support groups and counseling are beneficial.

When to call your doctor

• New onset of severe abdominal pain or vomiting.
• Persistent diarrhea (>3 watery stools/day for >2 weeks).
• Unexplained weight loss >5 % of body weight.
• Signs of bleeding (black/tarry stools, vomiting blood).

Prevention

Because most gastrinomas arise sporadically, primary prevention is limited. However, the following measures can reduce complications and may lower risk in predisposed individuals:

• Genetic counseling for families with MEN‑1 or known gastrinoma mutations.
• Avoid chronic PPI overuse without indication – paradoxically, long‑term high‑dose PPIs can mask early ulcer disease, delaying diagnosis.
• Eradicate H. pylori infection if present, to reduce additive ulcer risk.
• Smoking cessation – smoking promotes neuroendocrine tumor growth.
• Routine health checks for individuals with known MEN‑1; annual biochemical screening (fasting gastrin, calcium, parathyroid hormone).

Complications

If left untreated or poorly controlled, Zollinger‑Ellison syndrome can lead to serious health problems:

• Perforated duodenal ulcer – emergency surgical repair required.
• Gastrointestinal bleeding – can be life‑threatening.
• Severe malabsorption – protein‑calorie deficiency, anemia, osteoporosis.
• Electrolyte disturbances – hypokalemia, metabolic alkalosis.
• Metastatic gastrinoma – liver, lymph nodes, or bone spread; impacts survival.
• Secondary pancreatic insufficiency – due to acid inactivation of pancreatic enzymes.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Accessed June 2026.
2. National Institute of Diabetes and Digestive and Kidney Diseases. Zollinger‑Ellison Syndrome. Updated 2024.
3. American College of Gastroenterology. Guideline for Diagnosis and Management of ZES. 2023.
4. World Health Organization. Neuroendocrine Tumours Fact Sheet. 2022.
5. Cleveland Clinic. Zollinger‑Ellison Syndrome. 2024.

```